Irvine-based Cortex Pharmaceuticals, which is developing treatments for sleep apnea, reported this morning that it has received $2.0M in a Series F, convertible preferred stock financing from an unnamed, single institutional investor. The firm said the private placement would be used for working capital and general corporate purposes. Rodman & Renshaw LLC was the placement agent for the transaction.